A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis

Journal of Gastroenterology and Hepatology

Volumn 9, Issue 2, 1994, Pages 162-168

  TURNER, IAN B ^a   MYSZOR, MARGARET ^a   MITCHISON, HARRIET C ^a   BENNETT, MARK K ^a   BURT, ALISTAIR D ^a   JAMES, OLIVER F W ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

hydrophilic bile acids; primary biliary cirrhosis; ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HISTOLOGY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0028297244     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1994.tb01237.x     Document Type: Article

References (48)

1. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double‐blind trial
2. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
3. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis
4. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis
5. Improvement of biliary enzyme levels and itching as a result of long‐term administration of ursodeoxycholic acid in primary biliary cirrhosis
6. Ursodeoxycholic acid in primary biliary cirrhosis: No evidence for toxicity in the stages I to III
7. Ursodeoxycholic acid‐induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis
8. Influence of ursodeoxycholic acid (UDCA) on biochemical parameters in cholestatic liver disease (Abstr.)
9. A randomised controlled trial of ursodeoxycholic acid in primary biliary cirrhosis (Abstr.)
10. Ursodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): A double‐blind multicenter trial (Abstr.)
11. The Canadian multi‐centre double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis (Abstr.)
12. Ursodeoxycholic acid is beneficial therapy for patients with primary biliary cirrhosis (Abstr.)
13. Prognosis in primary biliary cirrhosis: Model for decision making
14. Ursodeoxycholic acid (UDCA) (Abstr.). reduces secondary liver damage in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) (Abstr.)
15. Ursodeoxycholic acid therapy for primary biliary cirrhosis: Progression of disease despite near normalization of biochemical liver tests (Abstr.)
16. No symptomatic or histological benefit from ursodeoxycholic acid treatment in PBC after 1 year controlled pilot study (Abstr.)
17. Treatment of pruritus in primary biliary cirrhosis with rifampicin
18. Opioid peptides and primary biliary cirrhosis
19. Failure of rifampicin to relieve pruritus in chronic liver disease
20. Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis
21. A prospective trial of colchicine in primary cirrhosis
22. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis
23. Bile acids, liver injury, and liver disease
24. Hepatic toxicity in the Rhesus monkey treated with chenodeoxycholic acid for six months — Biochemical and ultrastructual studies
25. Lithocholate cholestasis‐sulfated glycolithocholate‐induced intrahepatic cholestasis in rats
26. Lithocholate glucuronide is a cholestatic agent
27. Influence of hydroxylation and conjugation of bile salts on their membrane‐damaging properties‐studies on isolated hepatocytes and lipid membrane vesicles
28. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat
29. Hepatic injury induced by bile salts: Correlation between biochemical and morphological events
30. Taurodeoxycholate prevents taurolithocholate‐induced cholestasis and toxicity in rat liver
31. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts
32. Mechanisms of cholestasis. 6. Bile acids in human livers with or without biliary obstruction
33. Ursodeoxycholic acid versus chenodeoxycholic acid: Comparison of their effects on bile acid and bile lipid composition in patients with cholesterol gallstones
34. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones
35. Effect of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytes
36. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes
37. Long‐term treatment of primary biliary cirrhosis with ursodeoxycholic acid: The third year of a controlled trial
38. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids
39. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man
40. Ursodeoxycholic acid protects basolateral liver plasma membranes against toxic bile acid salts (Abstr.)
41. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes
42. Ursodeoxycholate reduces glycochenodeoxycholate‐induced toxicity in human primary hepatocytes but not in human hepatoma cells
43. Hepatic expression of class I and class II major histocompatibility molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid
44. Immunomodulatory effects of ursodeoxycholic acid on immune responses
45. Immunomodulatory effects of ursodeoxycholic acid on immune responses
46. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor‐alpha production by monocytes
47. New strategies needed for treatment of primary biliary cirrhosis